A new analysis from the randomised phase 3 NRG/RTOG 0815 trial suggests that the Decipher genomic classifier may do more than estimate prognosis: it may help predict which men with intermediate-risk prostate cancer actually benefit from adding short-term androgen deprivation therapy to dose-escalated radiotherapy. Researchers analysed tumour samples from 395 men, with a median follow-up […]
The phase II SOAR trial suggests that metastasis-directed therapy (MDT) alone may delay the need for androgen deprivation therapy in carefully selected men with PET-defined oligorecurrent prostate cancer. Twenty patients with up to ten nodal or bone metastases after radical prostatectomy received radiotherapy, salvage lymph-node dissection, or both, without concurrent ADT. At six months, 40% […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Another encouraging week for prostate cancer research, with several promising developments worth watching. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. Clinical […]
A prospective clinical trial is testing whether artificial intelligence can help determine which men with intermediate-risk prostate cancer really need short-term androgen deprivation therapy alongside radiotherapy. The ASTuTE study uses the ArteraAI Prostate Test, which analyses digitised biopsy images together with clinical information to estimate both the risk of future metastasis and the likelihood that […]
Most radioligand therapies rely on a single molecular target. INN02 takes a different approach, combining two targets in the same molecule: fibroblast activation protein (FAP) and integrin αvβ3, both found in the tumour microenvironment. The same compound can be labelled with gallium-68 for PET imaging or lutetium-177 for therapy, creating a true theranostic platform. In […]
The story around aglatimagene besadenovec (CAN-2409) has become more interesting (we already talked about it in this article). The phase 3 PrTK03 trial had already shown that adding this locally injected viral immunotherapy to radiotherapy improved disease-free survival in men with intermediate- to high-risk localised prostate cancer. New biomarker data now provide a biological explanation […]
A new study suggests that ATM alterations could identify a subgroup of metastatic castration-resistant prostate cancer particularly likely to benefit from 177Lu-PSMA-617 (Pluvicto). The retrospective analysis included 205 men with mCRPC treated with Lu-177-PSMA-617 between 2022 and 2026, all of whom had next-generation DNA sequencing available. ATM alterations were present in 12.7% of patients and […]
Most cancer drugs attack something on the tumour cell: a receptor, an enzyme, a signalling pathway or a surface protein. TTX-MC138 takes a different approach. It is designed to inhibit microRNA-10b (miR-10b), a small regulatory RNA strongly associated with invasion, metastatic progression and survival of metastatic tumour cells. The idea is unusually ambitious: rather than […]
PSMA has transformed prostate cancer imaging and radioligand therapy, but it is not the only useful target on prostate cancer cells. A new pivotal trial, SPARROW, is now testing 68Ga-DOTA-RM2, a PET tracer that targets the gastrin-releasing peptide receptor, or GRPR, in men with prostate cancer. The study is designed to determine how accurately GRPR-PET […]
For men with localised low- or intermediate-risk prostate cancer who need treatment, one of the biggest decisions is whether to choose surgery or radiotherapy. The phase 3 PACE-A trial is the first randomised study to directly compare modern prostatectomy with stereotactic body radiotherapy (SBRT) delivered in just five treatments. New long-term results presented at ASTRO […]